Australia markets close in 52 minutes
  • ALL ORDS

    7,648.40
    +85.90 (+1.14%)
     
  • ASX 200

    7,318.20
    +78.40 (+1.08%)
     
  • AUD/USD

    0.7145
    +0.0003 (+0.04%)
     
  • OIL

    70.77
    +0.82 (+1.17%)
     
  • GOLD

    1,790.10
    +4.90 (+0.27%)
     
  • BTC-AUD

    80,155.34
    -724.68 (-0.90%)
     
  • CMC Crypto 200

    1,445.73
    +16.80 (+1.18%)
     
  • AUD/EUR

    0.6321
    -0.0001 (-0.01%)
     
  • AUD/NZD

    1.0463
    +0.0001 (+0.01%)
     
  • NZX 50

    12,735.54
    +203.88 (+1.63%)
     
  • NASDAQ

    16,399.24
    +373.66 (+2.33%)
     
  • FTSE

    7,109.95
    +65.92 (+0.94%)
     
  • Dow Jones

    35,135.94
    +236.60 (+0.68%)
     
  • DAX

    15,280.86
    +23.82 (+0.16%)
     
  • Hang Seng

    23,591.68
    -260.56 (-1.09%)
     
  • NIKKEI 225

    28,482.90
    +198.98 (+0.70%)
     

Takara Bio USA, Inc. Launches Automated, Full-Length Single-Cell RNA-seq Solution for Enhanced Biomarker Discovery

·2-min read

SAN JOSE, Calif., October 18, 2021--(BUSINESS WIRE)--Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the SMART-Seq® Pro kit for the ICELL8® cx Single-Cell System. This automated single-cell RNA-seq solution allows scientists to generate full-length transcriptome data from over 1,500 single cells simultaneously and from a wide range of sample types—even large, delicate adult cardiomyocytes.

While single-cell RNA sequencing has exploded in popularity over the last 10 years, two significant challenges remain: maintaining the sensitivity of the assay during miniaturization and interrogating full-length mRNA transcripts for potential biomarkers. "Due to the limitations of most single-cell systems, scientists can only look for potential biomarkers at the ends of mRNA transcripts, and sensitivity is sacrificed for throughput," commented Carol Lou, President and CEO of Takara Bio USA. "Our new SMART-Seq Pro technology for the ICELL8 cx system, together with our bioinformatic tools, overcome these limitations, delivering full-length transcript information and enabling easy data analysis to power biomarker discovery."

The ICELL8 cx Single-Cell System is an advanced, integrated automation platform for imaging and dispensing thousands of single cells in 5,184-nanowell chips. With the launch of the SMART-Seq Pro kit for the ICELL8 cx system, Takara Bio USA has created an end-to-end solution for sensitive transcriptome analysis of up to eight samples at once. With the integrated Cogent™ Analysis Pipeline and Cogent Discovery software, scientists can analyze their samples for rare biomarkers like isoforms, gene fusions, and single nucleotide variants, which are missed with other systems.

Learn more by viewing data and other technical information.

About Takara Bio USA

Takara Bio USA, Inc. is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.

About Takara Bio Inc.

Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP reagents to contracted cell and gene therapy manufacturing services, and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005102/en/

Contacts

Lorna Neilson, PhD
VP, Corporate Development
lorna_neilson@takarabio.com
650.919.7372

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting